Premium
The anti‐emetic efficacy of maropitant (Cerenia™) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe
Author(s) -
De la PuenteRedondo V. A.,
Siedek E. M.,
Benchaoui H. A.,
Tilt N.,
Rowan T. G.,
Clemence R. G.
Publication year - 2007
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/j.1748-5827.2006.00321.x
Subject(s) - metoclopramide , medicine , antiemetic , anesthesia , nausea , vomiting
O bjectives :The efficacy of maropitant (Cerenia™; Pfizer Inc.) as an anti‐emetic for use in dogs with ongoing emesis was evaluated in a two‐phase multi‐centric study conducted at veterinary clinics in France, Italy, Slovakia and the UK.M ethods :In phase I, dogs with ongoing emesis were randomised in a 1:1 ratio to either maropitant (32 dogs) or metoclopramide (34 dogs). In phase II, dogs were randomised in a 2:1 ratio to maropitant (77 dogs) or metoclopramide (40 dogs). Maropitant was administered subcutaneously at 1 mg/kg/day for up to five days. Metoclopramide was administered as recommended on the product labels as licensed at 0·5 to 1 mg/kg/day subcutaneously or orally with the daily dose divided over two to three administrations per day for up to three to five days.R esults :In phase I, 97 per cent of dogs treated with maropitant and 71 per cent of dogs treated with metoclopramide did not vomit after treatment (P<0·01). The mean number of emetic events after maropitant treatment was significantly reduced compared with that after metoclopramide treatment (P=0·01). In phase II, the occurrence of emesis was lower for maropitant during the first 24 hours (P<0·0001) and for each day thereafter.C linical S ignificance :A single daily dose of maropitant was more effective than metoclopramide administered two or three times daily in the treatment of emesis caused by various aetiologies in dogs.